NCT04210713View on ClinicalTrials.gov

Neuroimmune Dysfunction in Alcohol Use Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

February 3, 2020

Primary Completion Date

September 20, 2023

Study Completion Date

September 20, 2023

Conditions
Alcohol DrinkingAlcohol-Related DisordersDiseaseInflammationAlcoholismCognitive DysfunctionPathologic ProcessesDrinking BehaviorSubstance-Related DisordersChemically-Induced DisordersMental DisorderCognition DisorderNeurocognitive DisordersMinocyclineAnti-Bacterial AgentsAnti-Infective Agents
Interventions
DRUG

Minocycline

200 mg/day

DRUG

Sugar pill

Matched placebo

Trial Locations (1)

21228

Maryland Psychiatric Research Center (MPRC) Treatment Research Program (TRP), Catonsville

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

University of Maryland, Baltimore

OTHER

NCT04210713 - Neuroimmune Dysfunction in Alcohol Use Disorder | Biotech Hunter | Biotech Hunter